7 results about "Benzazepines" patented technology

A benzazepine fused ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and / or treatment of diseases related to vasopressin receptors.

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

The invention belongs to the technical field of medicinal chemistry, and relates to a benzazepine compound or pharmaceutically acceptable salt thereof as well as a preparation method and application of the benzazepine compound, in particular to a compound with a structural general formula as shown in a formula (I). The benzoazepine compound disclosed by the invention has a remarkable curative effect on treating brain organic lesion diseases, including vascular lesion and degenerative lesion, especially vascular dementia, Alzheimer's disease and cholinergic deficiency related diseases. Formula (I).

The present disclosure relates to compositions and methods, including prodrugs of (S)-3-(3-(((3,4- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzo[d]azepin-2-one that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, sinus tach (e.g. inappropriate sinus tachycardia (IST)), postural orthostatic tachycardia syndrome (POTS), coronavirus (COVID-19) (e.g. long COVID) and COVID-associated cardiovascular abnormalities, supraventricular tachycardia (SVT), tachycardia (e.g. rapid heart rate, atrial tachycardia), heart failure (e.g. congestive heart failure (CHF), systolic heart failure, pediatric heart failure, chronic heart failure), myocardial ischaemia, angina (e.g. angina pectoris), myocardial infarct, rhythm disturbances (e.g. supraventricular rhythm disturbances), chest pain, cardiomyopathy, coronary artery disease, and left ventricular dysfunction (LVD).

Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. Specifically, disclosed is a class of benzazepine fused ring derivatives as V2 receptor antagonists.

The present invention is based on the system Xc - Compounds of formula (I) or pharmaceutically acceptable salts thereof are useful in the treatment of diseases and / or disorders in which [Formula 1] JPEG2026505789001043.jpg5648 Regarding.

This invention belongs to the field of synthesis of benzo[b]azapyrrolizidine derivatives, specifically disclosing an antitumor active molecule, a benzo[b]azapyrrolizidine derivative, its synthesis method, and its application. This invention uses a transition metal Pd catalyst to generate a benzo[b]azapyrrolizidine derivative active molecule, as shown in general formula (2), from an acetylacetamide of general formula (1) in the presence of a ligand, a basic substance, and a solvent, under a nitrogen atmosphere and irradiation with light at a wavelength of 420–500 nm. This invention achieves the synthesis of structures containing benzo[b]azapyrrolizidine molecular fragments through a free radical relay tandem cyclization reaction from aryl to alkyl to vinyl groups catalyzed by transition metal Pd, realizing the synthesis of such molecules. Furthermore, a series of synthesized benzo[b]azapyrrolizidine molecules and their derivative active molecules have been tested and found to possess antitumor activity.